I saw an interview of someone from a company that says they have a potential 
vaccine. They explained that it is NOT a vaccine that works by causing an 
immune response, but that it is the actual antibodies themselves, that your 
body would have produced. The production of these antibodies is (I suppose) 
CRISPR'd into some single-cell organism, then cultured in mass quantities. 
Safety is of course still an issue; but someone would not catch the disease 
itself from the vaccine. 

Also, it would be a treatment as well as a preventive. The hope is that this 
process could be tested and brought to market more quickly than the usual 
vaccine process.

Greg

-----Original Message-----
From: Mercedes [mailto:mercedes-boun...@okiebenz.com] On Behalf Of archer75--- 
via Mercedes
Sent: Friday, March 13, 2020 9:24 AM
To: Mercedes Discussion List
Cc: arche...@embarqmail.com
Subject: [MBZ] Coronavirus Vaccine




Philly vaccine pioneer: We can’t rush a coronavirus vaccine | Q&A


At a White House news conference Tuesday, Anthony Fauci, the head of the 
National Institute of Allergy and Infectious Disease, told President Donald 
Trump a coronavirus vaccine would likely not be available within the next year 
or two. Trump responded: “I like the sound of a couple of months better.”

But a vaccine is not going to be available in the next couple of months, and 
according to Dr. Paul Offit, that’s appropriate. Offit, director of the Vaccine 
Education Center at Children’s Hospital of Philadelphia, is the co-developer of 
the rotavirus vaccine. It took roughly 26 years to perfect that protection 
against a disease that, according to the Centers for Disease Control and 
Prevention, was the leading cause for severe diarrhea in children before the 
vaccine’s introduction in 2006.

Why is it unrealistic to expect a vaccine for coronavirus in a few months?

Nobody’s ever seen this virus before. Therefore, if you’re interested in making 
a vaccine, you first had access to that virus only a couple months ago. That’s 
not long.

[To make a vaccine] you first need to make a decision as to what approach you 
want to take. Then you have to do extensive animal model testing to make sure 
that the approach that you’ve taken is safe in animals, and that it induces an 
immune response which would likely be protective. Then you gradually do studies 
in people to make sure it’s safe, and then to make sure that it induces an 
immune response. That takes time, a lot of time, typically years. Then and only 
then, are you ready to put it into people to see whether or not it works in an 
outbreak situation.

In 2018, after the World Health Organization declared an Ebola outbreak in the 
Democratic Republic of Congo, there was an experimental vaccine very quickly.

I think people got fooled by Ebola. When the outbreak occurred in West Africa 
and we had a vaccine pretty much that rolled off shelf within weeks, people 
thought, Ha! That’s easy.

But what they didn’t realize is people have been working on an Ebola vaccine 
for 20 years. They’ve done the animal model testing. They’ve done the testing 
to make sure that the vaccine was safe and was immunogenic.

But that’s not true here. This is a new virus. So we’re starting from scratch.

What is it about this virus that makes people confident that a vaccine will be 
available?

I don’t know. You know, I’d say about 15% to 20% of the respiratory infections 
that we see in our hospital in the winter months are [types of] coronavirus. 
This is a virus that has been around for 50 years.

But here are these three newer strains of coronavirus — MERS, SARS, and now 
this COVID-19. The first two viruses, SARS and MERS, have come and gone.

I think this [COVID-19] virus likely will come back because it’s different. If 
you were infected with SARS or MERS viruses, you were sick. And it’s very easy 
to tell who was sick and who wasn’t. You could then quarantine those people — 
put a moat around them, if you will — so that they wouldn’t infect others. So 
those infections quickly died out. This virus is more like flu. It spreads in a 
similar manner to flu by respiratory droplet. It’s about as contagious as flu. 
It has the same set of symptoms as flu. And I think in the end, frankly, it’s 
going to have the same mortality rate as flu.

There are certainly human studies showing that if you’re infected with a 
coronavirus — meaning one of the typical coronaviruses — you can have immunity 
to that strain for at least a year and probably longer. That’s encouraging. If 
natural infection can protect you, then it’s encouraging that it can produce an 
immune response which is protective and which you should be able to mimic with 
vaccination.

Vaccine development is tightly regulated. How much of that is about safety vs. 
red tape?

If you’re going to be testing this in otherwise healthy people who are very, 
very unlikely to die from this infection, you better make sure it’s safe. So 
you want those regulations in place.

An example is the dengue vaccine. When it was tested in Latin America and 
Philippines, it was found to actually increase your risk of dengue shock 
syndrome. Children who were less than 9 years of age, who had never been 
exposed to the virus before, were actually more likely to be hurt by the 
vaccine than helped by it. Now, you only knew that from doing large clinical 
trials with tens of thousands of people.

The history of medical breakthroughs is littered with tragedy. You want to make 
sure that things are safe.

What do you think is behind the apparent willingness to skirt the rules to rush 
a vaccine?

I think that because we falsely overrate, or incorrectly rate, what the 
mortality rate is, we’re willing to accept that things will be rushed through. 
In fact, coronavirus doesn’t have a high mortality rate.

There’s a virus that the CDC currently estimated has killed between 20,000 and 
45,000 people in the United States -- influenza. But only half the country gets 
that vaccine.

There’s only 14 deaths [in the U.S., as of Friday afternoon] from COVID-19, but 
everybody would get a vaccine now.

The point being: We’re not very good at assessing risk.

https://www.inquirer.com/health/coronavirus/coronavirus-covid-19-vaccine-trump-paul-offit-20200306.html

Gerry
........................................................................


_______________________________________
http://www.okiebenz.com

To search list archives http://www.okiebenz.com/archive/

To Unsubscribe or change delivery options go to:
http://mail.okiebenz.com/mailman/listinfo/mercedes_okiebenz.com



_______________________________________
http://www.okiebenz.com

To search list archives http://www.okiebenz.com/archive/

To Unsubscribe or change delivery options go to:
http://mail.okiebenz.com/mailman/listinfo/mercedes_okiebenz.com

Reply via email to